A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT01630733. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to compare overall survival of participants randomized to receiving custirsen in combination with docetaxel with participants randomized to receive docetaxel alone.
Study identification
- NCT ID
- NCT01630733
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 664 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 23, 2012
- Primary completion
- Nov 16, 2016
- Completion
- Nov 16, 2016
- Last update posted
- Apr 14, 2026
2012 – 2016
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University Cancer Institute | Boynton Beach | Florida | — | — |
| Florida Hospital | Orlando | Florida | — | — |
| University Cancer and Blood Center, LLC | Athens | Georgia | — | — |
| Joliet Oncology-Hematology Associates Ltd. | Joliet | Illinois | — | — |
| Kentucky Cancer Clinic | Hazard | Kentucky | 33426 | — |
| Missouri Baptist Cancer Center | St Louis | Missouri | — | — |
| Novant Health | Winston-Salem | North Carolina | — | — |
| Summa Health System | Akron | Ohio | — | — |
| Aultman Hospital | Canton | Ohio | — | — |
| Center for Biomedical Research LLC | Knoxville | Tennessee | — | — |
| Sarah Cannon Cancer Center | Nashville | Tennessee | — | — |
| Blood and Cancer Center of East Texas | Tyler | Texas | — | — |
| Tyler Hematology/Oncology PA | Tyler | Texas | — | — |
| Virginia Cancer Specialists (Leesburg) - USOR | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01630733, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01630733 live on ClinicalTrials.gov.